Recent Updates
Recently added Catalysts
ATYR Positive Sentiment

Anti-Fibrotic Activity Observed Across Preclinical Models of Pulmonary and Renal Fibrosis for a Potential Therapeutic Based on Asp-tRNA Synthetase

Monday, December 9, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the promising anti-fibrotic activity of a potential therapeutic based on Asp-tRNA synthetase, observed across various preclinical models targeting pulmonary and renal fibrosis. The findings suggest significant therapeutic potential, highlighting the importance of this research in addressing fibrotic diseases. The company aTyr is actively advancing its R&D pipeline in this area.
Price reaction · baseline $3.59 (2024-12-09T19:30:00.000Z) · hit during market hours · 4 other ATYR headline(s) in the window, move may be shared
day 0 close · peak
-1.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Anti-fibrotic activity observed in preclinical models.
  • Potential therapeutic benefits for pulmonary and renal fibrosis.
  • Research supports the efficacy of Asp-tRNA synthetase.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
5.7%
average across 7 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
Efzofitimod/kg
Phase 3 · Pulmonary Sarcoidosis

Full Press Release Details

• Company About Us Leadership Team Board of Directors Advisors Contact
• Our Science Extracellular t RNA Synthetase Biology Intellectual Property Publications, Posters and Presentations
• R&D Pipeline Efzofitimod Research Programs Pangu
• Patients Clinical Trials About Pulmonary Sarcoidosis About SSc-ILD EFZO-CONNECT ™ Expanded Access Policy
• Careers Working at aTyr Career Opportunities
• Investors and Media Corporate Governance Board of Directors Board Committees News Releases SEC Filings Stock Information Analyst Coverage Investor Alerts Events and Webcasts Media
• Privacy Policy
• About Us
• Leadership Team
• Board of Directors
• Advisors
• Contact
• Extracellular t RNA Synthetase Biology
• Intellectual Property
• Publications, Posters and Presentations
• Pipeline
• Efzofitimod
• Research Programs
• Pangu
• Clinical Trials
• About Pulmonary Sarcoidosis
• About SSc-ILD
• EFZO-CONNECT ™
• Expanded Access Policy
• Working at aTyr
• Career Opportunities
• Corporate Governance Board of Directors Board Committees
• News Releases
• SEC Filings
• Stock Information
• Analyst Coverage
• Investor Alerts
• Events and Webcasts
• Media
• Board of Directors
• Board Committees

Frequently Asked Questions

What is the focus of the research discussed?

The research focuses on the anti-fibrotic activity of a potential therapeutic based on Asp-tRNA synthetase.

What diseases are targeted by the potential therapeutic?

The potential therapeutic targets pulmonary and renal fibrosis.

What were the findings from the preclinical models?

The findings indicate significant anti-fibrotic activity across various preclinical models.

Which company is advancing this research?

The company advancing this research is aTyr.

ShareAdd on Google
Tags: ATYR Viatris Investor Conferences Healthcare aTyr Asp-tRNA synthetase pulmonary fibrosis renal fibrosis preclinical models
Last updated: Dec 9, 2024

Biotech snapshot

Cash runway
$57M liquidity · $3M/mo burn
~18 mo
Low dilution risk
Lead asset
Efzofitimod/kgPhase 3
Pulmonary Sarcoidosis →

Catalyst track record

+41%
best trade around ATYR's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for ATYR.

See every catalyst's timing & PoA →